CCIA
TRVI icon

Campbell & Co Investment Adviser’s Trevi Therapeutics TRVI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
81,874
+41,829
+104% +$608K 0.08% 404
2026
Q1 		$478K Sell
40,045
-31,052
-44% -$348K 0.03% 767
2025
Q4 		$890K Buy
71,097
+46,212
+186% +$534K 0.04% 609
2025
Q3 		$228K Buy
24,885
+11,137
+81% +$83.5K 0.02% 983
2025
Q2 		$75.2K Buy
+13,748
New +$85.5K ﹤0.01% 1093

Other funds holding TRVI

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Campbell & Co Investment Adviser's TRVI Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Trevi Therapeutics (TRVI) stake by 104% in Q2 2026, buying an estimated $608K and bringing the position to 81,874 shares worth $1.53M. The position accounts for 0.08% of the portfolio, ranked #404.

Campbell & Co Investment Adviser first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. 40 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Campbell & Co Investment Adviser held 81,874 shares of Trevi Therapeutics worth $1.53M as of Q2 2026.
  • Campbell & Co Investment Adviser bought 41,829 Trevi Therapeutics shares in Q2 2026, an estimated $608K.
  • Trevi Therapeutics made up 0.08% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #404 holding.
  • Campbell & Co Investment Adviser first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 40 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.